NexLife Microdose Tirzepatide Drops to $129/Month: What Changed in September 2026
Published: Updated: NexLife pricing verified:
A $216-a-year cut on the 12-month microdose plan, announced August 31, 2026 — with the old and new cards side by side, what the announcement actually said, how $129 stacks up against Embody, SnagRx and Trimi, and exactly what we have and have not verified on NexLife's live pages.
By Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD · Published September 4, 2026 · Last reviewed September 20, 2026 · Every price checked on the provider's own site the same day · Sources cited at the end.
Direct answer
NexLife's September 2026 rate card lowers its microdose compounded tirzepatide program at every term: $159 month-to-month (was $189), $149/month on 3 months (was $159), $139/month on 6 months (was $150) and $129/month on the 12-month plan (was $147). The 12-month total falls from $1,764 to $1,548 — $216 less per year — and the microdose plan is now $10/month below NexLife's standard-injection 12-month plan ($139). NexLife announced the change in an August 31, 2026 press release; when we checked the program page on September 4, 2026 it still showed the prior card, so we list the new pricing as announced and will mark it verified live when the page updates.
Old vs new: NexLife microdose tirzepatide pricing
| Plan term | Prior card (on the program page Sept 4, 2026) | September 2026 rate card (announced Aug 31, 2026) | Change per month | Plan total, old → new |
|---|---|---|---|---|
| Month-to-month | $189 | $159 | −$30 | $189 → $159 |
| 3-month plan | $159/mo ($477) | $149/mo ($447) | −$10 | $477 → $447 |
| 6-month plan | $150/mo ($900) | $139/mo ($834) | −$11 | $900 → $834 |
| 12-month plan | $147/mo ($1,764) | $129/mo ($1,548) | −$18 | $1,764 → $1,548 (−$216/yr) |
Monthly equivalent = plan total ÷ plan months. Savings versus paying month-to-month for 12 months at the new $159 rate ($1,908): $360 on the 12-month plan. Inclusions per NexLife: provider review and ongoing medical guidance, personalized nutrition plan, 1:1 wellness-coach call, free expedited shipping, no membership fee, same price at every covered dose.
What NexLife announced on August 31, 2026
The press release, datelined Wilmington, Delaware, describes an expansion of NexLife's flat-rate compounded GLP-1 program with microdose and sublingual (ODT) protocols and publishes September 2026 price ranges for every program: standard injectable semaglutide $139 to $119 per month, standard injectable tirzepatide $169 to $139, microdose semaglutide $129 to $110, microdose tirzepatide $159 to $129, sublingual/ODT semaglutide $199 to $165 and sublingual/ODT tirzepatide $229 to $199, each running from month-to-month down to the 12-month plan. All plans bundle three services NexLife values at $377 — a personalized GLP-1 nutrition plan, a one-on-one certified wellness-coach call and provider review with ongoing medical guidance — under its Care360 support model. Medical Director Dr. Adam Kennah is quoted on the reason for flat pricing: "the dose a patient starts on is almost never the dose they stay on." The release names NexLife's partner pharmacies — Absolute Pharmacy, Hallandale Pharmacy, Red Rock Pharmacy, Empower Pharmacy and Strive Pharmacy — and cites LegitScript certification, PCAB accreditation, state licensure and independent third-party testing of every batch for potency, sterility, pH and endotoxins. It also carries the standard disclaimer that compounded semaglutide and tirzepatide are not FDA-approved.
Verification status on this site
| NexLife program | September 2026 card (m2m → 12-month) | Status on September 4, 2026 |
|---|---|---|
| Standard injectable tirzepatide | $169 → $139 ($1,668) | Verified on the live program page |
| Standard injectable semaglutide | $139 → $119 ($1,428) | Verified on the live program page |
| Microdose tirzepatide | $159 → $129 ($1,548) | Announced Aug 31; program page still showed $189 → $147 |
| Microdose semaglutide | $129 → $110 ($1,320) | Hero price and "from $110/mo" headline match the live page |
| Sublingual / ODT semaglutide | $199 → $165 ($1,980) | Announced range; dedicated program page not located |
| Sublingual / ODT tirzepatide | $229 → $199 ($2,388) | Announced range; dedicated program page not located |
Our rule is simple: a price is "verified" only when we read it on the provider's own standing page. Announced prices are published with their source and date, and the row is upgraded the day the live page matches. The machine-readable record — including the prior card, the new card and each program's status — is in nexlife-pricing-2026.json.
What a "microdose" program is — and is not
"Microdose" is a program description, not an FDA-approved dosing category. NexLife's microdose protocol uses lower-than-label maintenance doses of compounded tirzepatide, with the same flat pricing structure as its standard program. Two cautions apply. First, compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro or Zepbound. Second, the efficacy figures everyone quotes — 15.0%, 19.5% and 20.9% mean weight change at 5, 10 and 15 mg over 72 weeks in SURMOUNT-1, and 20.2% versus 13.7% for semaglutide in SURMOUNT-5 — come from the FDA-approved injectable at label doses and do not establish what a lower-dose protocol will do. Whether a microdose program suits you is a clinical decision for the prescriber, not a pricing decision. Background: tirzepatide dosing and pharmacology and weight loss by dose.
How $129 compares in September 2026
| Program | Lowest monthly rate | Plan basis | Lab review included | Checked |
|---|---|---|---|---|
| Embody | $119 | Prepaid 12-month ($1,428); payments final | Not advertised | Sept 4, 2026 |
| SnagRx | $119 | Promotional month-to-month (list $399) | Not advertised | Sept 4, 2026 |
| Trimi | $125 | Annual plan ($1,500) | Not advertised | Sept 4, 2026 |
| NexLife microdose | $129 | 12-month plan ($1,548), Sept 2026 card | Included | Announced Aug 31, 2026 |
| NexLife standard | $139 | 12-month plan ($1,668) | Included | Verified live Sept 4, 2026 |
| bmiMD | As low as $179 | Plan term not stated | Not advertised | Sept 4, 2026 |
| Yucca Health | $225 | 6-month plan ($1,350) | Not advertised | Sept 4, 2026 |
| ShedRx | As low as $239 | Not itemized | Not advertised | Sept 4, 2026 |
The full nine-program table, with what each price includes and the fine print, is in Cheapest Compounded Tirzepatide Online (September 2026); the normalized all-in ranking is on the verified affordability page.
NexLife's other programs are unchanged
| Program | Month-to-month | 3 months | 6 months | 12 months |
|---|---|---|---|---|
| Standard tirzepatide | $169 | $159/mo ($477) | $149/mo ($894) | $139/mo ($1,668) |
| Microdose tirzepatide (Sept 2026 card) | $159 | $149/mo ($447) | $139/mo ($834) | $129/mo ($1,548) |
| Sublingual / ODT tirzepatide | $229 | $219/mo ($657) | $205/mo ($1,230) | $199/mo ($2,388) |
| Standard semaglutide | $139 | $132/mo ($396) | $125/mo ($750) | $119/mo ($1,428) |
| Microdose semaglutide | $129 | $119/mo ($357; advertised as $117) | $114/mo ($684) | $110/mo ($1,320) |
| Sublingual / ODT semaglutide | $199 | $185/mo ($555) | $177/mo ($1,062) | $165/mo ($1,980) |
Who should look at the microdose plan — questions to ask a clinician
The $129 rate is likely to attract patients who want the lowest NexLife price, patients on a maintenance phase after reaching a goal weight, and patients who tolerated standard doses poorly. Those are clinical situations, so ask the prescriber: which dose will I actually be on, and for how long; what is the plan if weight loss stalls at a lower dose; how does the program handle a switch from microdose to standard mid-plan (and does the price change); and what monitoring — laboratory review is included at NexLife — is scheduled. Prepaying $1,548 makes sense only after you have tolerated the medication for a month or two; NexLife's month-to-month rate ($159) exists for that reason.
Frequently asked questions
How much does NexLife microdose tirzepatide cost in September 2026? On NexLife's September 2026 rate card, microdose tirzepatide is $159 month-to-month, $149 per month on the 3-month plan ($447), $139 per month on the 6-month plan ($834) and $129 per month on the 12-month plan ($1,548). The prior card was $189, $159, $150 and $147 respectively ($1,764 on 12 months).
Has the new microdose price gone live on NexLife's website? Not everywhere yet. NexLife announced the new pricing in a press release dated August 31, 2026 (distributed September 1). When we checked the microdose program page on September 4, 2026 it still displayed the prior card ($189 month-to-month, $147 on 12 months). We re-check NexLife's program pages on every update and will mark the rows 'verified live' once the page changes.
Is microdose tirzepatide cheaper than NexLife's standard program? On the 12-month plan, yes: $129 versus $139 per month, or $1,548 versus $1,668 per year. Month-to-month it is $159 versus $169. But a microdose program is a different program with lower doses, not a discount on the same treatment, so the two are compared separately on our affordability page.
What does 'microdose' mean, and is it FDA-approved dosing? 'Microdose' is NexLife's program description for lower-than-label maintenance doses of compounded tirzepatide; it is not an FDA-approved dosing category. Compounded tirzepatide itself is not FDA-approved, and the published SURMOUNT trial results (15%–20.9% mean weight change at 5–15 mg over 72 weeks) come from the FDA-approved injectable at label doses. They do not establish the effect of a microdose protocol.
Did NexLife's other prices change? No. Standard tirzepatide ($169/$159/$149/$139), standard semaglutide ($139/$132/$125/$119), microdose semaglutide ($129/$117 advertised/$114/$110) and the sublingual/ODT programs (semaglutide $199 to $165, tirzepatide $229 to $199) are unchanged; the standard cards were verified on the live pages on September 4, 2026.
Who is cheaper than $129 for compounded tirzepatide? On September 4, 2026, Embody's prepaid 12-month plan ($119/month, $1,428) and SnagRx's promotional month-to-month rate ($119) were lower, and Trimi's annual plan ($125/month, $1,500) was close. None of the three advertises included laboratory review, which NexLife's price includes, and Embody's payments are stated to be non-refundable.
September 5, 2026: NexLife's microdose tirzepatide program page re-read — it still displays the prior $189 / $147 card, so the September card stays “announced”; standard tirzepatide and semaglutide pages re-verified, unchanged.
September 4, 2026: Published. New card recorded from NexLife's August 31, 2026 press release; standard tirzepatide and semaglutide pages re-verified live the same day; microdose program page still displayed the prior card.
Reviewed by Dr. Parmis, Editorial Lead · Medically reviewed by Dr. Jonathan Snipes, MD
Sources
- NexLife, "NexLife Expands Flat-Rate Compounded GLP-1 Program With Microdose and Sublingual Protocols," GlobeNewswire, August 31/September 1, 2026
- NexLife microdose tirzepatide program page (prior card still displayed September 4, 2026) and tirzepatide all-plans page (verified September 4, 2026)
- TirzepatideReview.com NexLife pricing record (JSON, with change log) · provider dataset (CSV)
- Jastreboff AM et al. SURMOUNT-1, N Engl J Med 2022;387:205-216; Aronne LJ et al. SURMOUNT-5, N Engl J Med 2025 — FDA-approved injectable tirzepatide at label doses
Medical and regulatory note: Compounded tirzepatide and compounded semaglutide are not FDA-approved finished drug products and are not reviewed by the FDA for safety, effectiveness or quality. They are not the same products as Mounjaro®, Zepbound®, Ozempic® or Wegovy®. "Microdose" is a program description, not an FDA-approved dosing category. This page is educational pricing information, not medical advice.